IN2014DN07812A - - Google Patents

Download PDF

Info

Publication number
IN2014DN07812A
IN2014DN07812A IN7812DEN2014A IN2014DN07812A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A IN 7812DEN2014 A IN7812DEN2014 A IN 7812DEN2014A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A
Authority
IN
India
Prior art keywords
reprogramming
methods
marks
epigenetic
mark readers
Prior art date
Application number
Inventor
Steven J M Jones
Oleksandr Yakovenko
Silvia Thoene
Pierre Yulmin Cheung
Jianghong An
Original Assignee
British Columbia Cancer Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency filed Critical British Columbia Cancer Agency
Publication of IN2014DN07812A publication Critical patent/IN2014DN07812A/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods of 'reprogramming' epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example loss of function or overactivity) that can contribute to certain diseases states such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.
IN7812DEN2014 2012-02-27 2013-02-27 IN2014DN07812A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603650P 2012-02-27 2012-02-27
US201261637282P 2012-04-24 2012-04-24
PCT/CA2013/050145 WO2013127011A1 (en) 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer

Publications (1)

Publication Number Publication Date
IN2014DN07812A true IN2014DN07812A (en) 2015-05-15

Family

ID=49081499

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7812DEN2014 IN2014DN07812A (en) 2012-02-27 2013-02-27

Country Status (11)

Country Link
US (1) US9552457B2 (en)
EP (1) EP2819662B1 (en)
JP (1) JP6137703B2 (en)
KR (1) KR102149860B1 (en)
CN (1) CN104136020B (en)
AU (1) AU2013225592B2 (en)
BR (1) BR112014021201B1 (en)
CA (1) CA2865675C (en)
IN (1) IN2014DN07812A (en)
RU (1) RU2637441C2 (en)
WO (1) WO2013127011A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920377B2 (en) * 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
WO2015033228A2 (en) * 2013-09-09 2015-03-12 Glionova Ab Compounds and use for treating cancer
EP3064205A1 (en) * 2015-03-06 2016-09-07 Glionova AB Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
CN107847678A (en) 2015-07-31 2018-03-27 赛诺菲-安万特德国有限公司 Sensor, cartridge case and delivery device
CN111885914B (en) * 2017-10-27 2022-05-13 投资健康有限责任公司 Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives
WO2022081892A1 (en) * 2020-10-14 2022-04-21 The Regents Of The University Of California Systems for and methods of determining protein-protein interaction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL283900A (en) 1960-04-26
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3622580A (en) 1969-03-25 1971-11-23 Smith Kline French Lab Piperazino-acetylamino-9-fluorenones and-anthraquinones
LU85246A1 (en) 1984-03-13 1985-10-14 R L Galephar Sa 2- (AMINOALKYL) ACRYLOPHENONES, THEIR PREPARATION AND THEIR USE
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
NZ510230A (en) * 1998-08-25 2004-01-30 Scripps Research Inst Predicting protein function by electronic comparison of functional site descriptors
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
CA2858520A1 (en) 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
WO2009015283A2 (en) 2007-07-24 2009-01-29 President And Fellows Of Harvard College Bhc80 - histone complexes and uses thereof
CN102369204A (en) 2008-09-26 2012-03-07 新加坡科技研究局 3-deazaneplanocin derivatives
WO2010045199A2 (en) 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
GB0822248D0 (en) * 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
AU2010278738A1 (en) 2009-07-31 2012-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
KR101857599B1 (en) * 2010-05-14 2018-05-14 다나-파버 캔서 인스티튜트 인크. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
RU2618475C2 (en) 2010-09-10 2017-05-03 Эпизайм, Инк. Human ezh2 inhibitors and methods of application thereof
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
CA2828212A1 (en) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
WO2012123119A1 (en) 2011-03-17 2012-09-20 Cellzome Ag Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins
WO2013059944A1 (en) * 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof

Also Published As

Publication number Publication date
EP2819662A1 (en) 2015-01-07
US20150154345A1 (en) 2015-06-04
JP6137703B2 (en) 2017-05-31
EP2819662B1 (en) 2019-04-10
BR112014021201B1 (en) 2023-01-24
EP2819662A4 (en) 2016-03-23
AU2013225592B2 (en) 2017-11-09
RU2014138543A (en) 2016-04-20
JP2015515448A (en) 2015-05-28
WO2013127011A1 (en) 2013-09-06
AU2013225592A2 (en) 2014-10-09
CN104136020A (en) 2014-11-05
CA2865675C (en) 2023-02-28
CA2865675A1 (en) 2013-09-06
AU2013225592A1 (en) 2014-10-09
KR102149860B1 (en) 2020-08-31
CN104136020B (en) 2018-08-28
BR112014021201A2 (en) 2021-06-08
US9552457B2 (en) 2017-01-24
KR20140132382A (en) 2014-11-17
RU2637441C2 (en) 2017-12-04

Similar Documents

Publication Publication Date Title
IN2014DN07812A (en)
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12015501868A1 (en) Inhibitors of histone demethylases
MX2015005963A (en) Heterocyclic glutaminase inhibitors.
MX2016001587A (en) Kdm1a inhibitors for the treatment of disease.
CO7141410A2 (en) Nitrogenous heterocyclic compound
BR112015005227A2 (en) glycosylceramide synthase inhibitors
NZ700515A (en) Biophotonic compositions, kits and methods
PE20151727A1 (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANE-3-CARBOXYL (BENZYL-CYAN-METHYL) -AMIDES SUBSTITUTED, CATEPSIN C INHIBITORS
MX350539B (en) Enediyne compounds, conjugates thereof, and uses and methods therefor.
MX362797B (en) Balloon catheter with enhanced locatability.
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
BR112016002069A2 (en) new fused pyrimidine compound or salt thereof
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
IN2012DN05192A (en)
BR112015029504A2 (en) kinase inhibitors
NZ627480A (en) Inhibitors of iap
MX2015013936A (en) Substituted condensed pyrimidine compounds.
BR112015021324A2 (en) 6- [4- (1h-imidazol-2-yl) piperidin-1-yl] pyrimidin-4-amine derivatives as kinase activity modulators
BR112015018047A2 (en) stable compositions comprising heparinoid, acute acting anesthetic and buffer
MX343517B (en) 2,4 substituted pyrimidinediamines for use in discoid lupus.
CL2015003563A1 (en) Marker for acid sphingomyelinase disorders and their uses.
MX2014013048A (en) Pantothenate derivatives for the treatment of neurologic disorders.
TN2015000020A1 (en) Molecular markers and methods for early sex determination in date palms
GB2514714A (en) Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue